TREATMENT ACCEPTABILITY AND ENGAGEMENT AMONGST PATIENTS ON ORAL AND INTRAVENOUS BISPHOSPHONATES: A QUALITATIVE STUDY

Narayanasamy, M.; Bishop, S.; Sahota, O.; Leonardi-Bee, J.; Paskins, Z.; Gittoes, N.; Ong, T.; Langley, T.; Cottrell, E.

Abstract

Objective: To explore treatment acceptability and engagement amongst patients prescribed oral and intravenous bisphosphonate treatment regimens for the prevention of osteoporotic fragility fractures.

Methods: Semistructured interviews were conducted with 78 patients aged 49 y and over, who had taken or received bisphosphonates within the previous 24 months for the prevention of fragility fractures. Data was analysed through iterative categorization (Neale, 2016), utilising the seven constructs of the Theoretical Framework of Acceptability (TFA, Sekhon et al., 2017) to compare the acceptability of oral (e.g., alendronic acid) and intravenous (e.g., zoledronic acid) bisphosphonate treatment regimens.

Results: Treatment acceptability and engagement were influenced by the extent to which patients had understanding around the prescribed treatment and associated regimen (intervention coherence), evidence of the treatment working, and/or expectancy that it would work (perceived effectiveness). Acceptability and engagement were compromised when patients could not meet the opportunity costs required to participate in the treatment, when treatment was perceived to be burdensome, and where patients’ values did not align with the treatment regimen (ethicality). The balancing of these factors contributed to how well patients were able to cope with the treatment regimen Aging Clin Exp Res (2022) 34 (Suppl 1):S35–S474 S309 123 (self-efficacy) and their overall emotional responses to treatment (affective attitudes). Intravenous treatments were generally perceived as easier to understand, more effective, less burdensome with fewer opportunity costs, and the preferrable regimen compared with oral bisphosphonates.

Conclusion: Intravenous bisphosphonate treatments were generally more acceptable to patients, perceived as more straightforward to engage in, although a portion of patients on oral bisphosphonates were satisfied with their current treatment. Further research is needed to identify whether findings are applicable to other patient groups.

Citation

Narayanasamy, M., Bishop, S., Sahota, O., Leonardi-Bee, J., Paskins, Z., Gittoes, N., Ong, T., Langley, T., & Cottrell, E. (2022, March). TREATMENT ACCEPTABILITY AND ENGAGEMENT AMONGST PATIENTS ON ORAL AND INTRAVENOUS BISPHOSPHONATES: A QUALITATIVE STUDY. Poster presented at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2022), Virtual

• Presentation Conference Type: Poster
• Conference Name: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2022)
• Start Date: Mar 24, 2022
• End Date: Mar 27, 2022
• Deposit Date: Jun 28, 2023
• Public URL: https://keele-repository.worktribe.com/output/510190
• Publisher URL: https://link.springer.com/article/10.1007/s40520-022-02147-3